CAS 1672668-24-4
:Belzutifan
Description:
Belzutifan, also known by its developmental code name, is a small molecule inhibitor that targets hypoxia-inducible factor 2 alpha (HIF-2α), a transcription factor involved in the regulation of various genes related to cellular response to low oxygen levels. This compound is characterized by its ability to disrupt the HIF-2α pathway, which is often overactive in certain cancers, particularly renal cell carcinoma. By inhibiting this pathway, Belzutifan aims to reduce tumor growth and improve patient outcomes. The substance is typically administered orally and has been studied for its efficacy in treating specific malignancies. Its chemical structure includes various functional groups that contribute to its pharmacological properties, including solubility and bioavailability. Belzutifan has undergone clinical trials to evaluate its safety and effectiveness, and it has received regulatory approval for use in certain indications. As with many targeted therapies, its use may be accompanied by specific side effects, necessitating careful monitoring during treatment.
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 5 products.
Ref: IN-DA01V3M7
1gTo inquire5gTo inquire10gTo inquire5mg109.00€25mg130.00€50mg160.00€100mg271.00€250mg609.00€Belzutifan
CAS:<p>"Belzutifan (MK-6482) is an oral HIF-2α inhibitor for ccRCC, with enhanced potency (IC50: 9 nM)."</p>Formula:C17H12F3NO4SPurity:99.34% - 99.88%Color and Shape:SolidMolecular weight:383.34PT2977
CAS:<p>PT2977 is a small-molecule inhibitor, which is derived from rational drug design, with a specific mode of action targeting hypoxia-inducible factor (HIF) pathways. This compound acts by selectively inhibiting HIF-2α, a critical driver of cellular response to hypoxic conditions, thus interfering with the transcription of genes involved in angiogenesis, erythropoiesis, and metabolic adaptation.</p>Formula:C17H12F3NO4SPurity:Min. 95%Molecular weight:383.34 g/mol
